PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

August 20, 2022

Study Completion Date

August 31, 2025

Conditions
Colorectal Cancer
Interventions
DRUG

PD-1 antibody + cox inhibitor

"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."

Trial Locations (2)

510655

RECRUITING

Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER